Actively Recruiting
Study of Optical Genome Mapping to Diagnose Blood Cancers in Patients with Suspected Hematologic Malignancies
Led by University Hospital, Brest · Updated on 2021-08-17
200
Participants Needed
4
Research Sites
208 weeks
Total Duration
AI-Summary
What this Trial Is About
Researchers are studying the potential of optical genome mapping to diagnose patients suspected of having hematologic cancers, including myelodysplastic syndromes MDS, acute lymphoblastic leukemia ALL, and other blood-related malignant neoplasms. This observational study aims to assess how this technology can identify chromosomal abnormalities involved in cancer development and progression. Participants provide samples that are analyzed using optical genome mapping to detect new chromosomal anomalies relevant to clinical outcomes and oncogenic pathways. The study tracks these findings from 2021 through 2026 to evaluate the diagnostic value of this method. During the study, patients samples are collected and examined in a chromosomal genetics laboratory. Researchers review chromosomal data to identify abnormalities linked to hematologic cancers. The study measures the ability of optical genome mapping to improve diagnosis. Participation involves no treatment instead, it focuses on sample analysis and genetic identification over several years, with a planned end in September 2026.
CONDITIONS
Brief Title
Optical Genome Mapping in Hematological Malignancies
Research Team
M
Marie-Bérengère, TROADEC, PhD
N
Nathalie DOUET-GUILBERT, MD, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
